The U.S. Agency for International Development (USAID) and the U.S. Department of State submit this report pursuant to Section 7019(e) of the Department of State, Foreign Operations, and Related Programs Appropriations Act, 2024 (Div. F, P.L. 118-47) and House Report 118-146, which states:
"Not later than 120 days after the date of the enactment of this Act, the Secretary of State and Administrator of USAID, in consultation with other relevant Federal departments and agencies, shall submit a report to the appropriate congressional committees detailing capabilities and capacity for vaccine design, testing, review, distribution, and manufacturing in low- and middle-income countries, including in Africa."
USAID and the U.S. Department of State, in collaboration with other Federal departments and agencies, provide support to augment and maximize utilization of capacity in low- and middle-income countries (LMIC) to design, test, review, and distribute vaccines against priority infections. The resulting strengthened capabilities in these countries will provide a return on investment many times over as they enable quality-assured vaccines to be manufactured more cost-effectively, reviewed more expeditiously, and distributed more efficiently and equitably to populations where they are needed most.
USAID expands access to vaccines by strategically building manufacturing capacity for quality-assured vaccines; strengthening regulatory systems, supply chains, and service delivery; and leveraging its global procurement volumes to encourage private sector investment and partnerships and improve global markets. For two decades, USAID has invested in increasing the global supply of quality-assured medicine and vaccines for priority disease areas, including through technical assistance to manufacturers in Africa and through its partnership with Gavi, the Vaccine Alliance across LMICs. USAID, in collaboration with the State Department, is also supporting a landscape analysis to investigate potential policy and investment pathways to increase the responsiveness of Latin American vaccine development and manufacturing capacities to outbreaks. In addition, USAID invests in strengthening regulatory authorities at the national and regional level, supply chain management, and pharmacy management systems to accelerate access to and appropriate use of quality-assured vaccine products that are safe and effective, facilitating a viable marketplace for manufacturers of quality health commodities, while removing falsified and substandard products from the market.
